Addex Reports Full Year 2025 Financial Results and Provides Corporate Update
Addex Therapeutics reported its full-year 2025 financial results, highlighting progress in its GABAB PAM chronic cough candidate, repositioning of dip...
Addex Therapeutics reported its full-year 2025 financial results, highlighting progress in its GABAB PAM chronic cough candidate, repositioning of dip...
Addex Therapeutics announced promising preclinical data for its GABAB positive allosteric modulator (PAM) candidate, showing significant anti-tussive ...